Allianz Asset Management Gmb H Y M Abs Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$8.22 - $15.13 $27,537 - $50,685	3,350 Added 11.66%	32,085 $485,000
Q1 2022 May 13, 2022	SELL	$6.55 - $17.42 $6,674 - $17,750	-1,019 Reduced 3.42%	28,735 $341,000
Q4 2021 Feb 11, 2022	SELL	$15.51 - $29.31 $117,876 - $222,756	-7,600 Reduced 20.35%	29,754 $482,000
Q3 2021 Nov 10, 2021	BUY	$27.47 - $37.31 $2,280 - $3,096	83 Added 0.22%	37,354 $1.07 Million
Q2 2021 Aug 16, 2021	BUY	$25.45 - $37.64 $279 - $414	11 Added 0.03%	37,271 $1.26 Million
Q1 2021 May 13, 2021	SELL	$29.16 - $51.96 $5,219 - $9,300	-179 Reduced 0.48%	37,260 $1.13 Million
Q4 2020 Feb 16, 2021	SELL	$37.86 - $54.26 $717,144 - $1.03 Million	-18,942 Reduced 33.6%	37,439 $1.85 Million
Q3 2020 Nov 13, 2020	SELL	$35.13 - $43.62 $53,081 - $65,909	-1,511 Reduced 2.61%	56,381 $2.16 Million
Q2 2020 Aug 14, 2020	SELL	$23.66 - $49.53 $93,125 - $194,950	-3,936 Reduced 6.37%	57,892 $2.5 Million
Q1 2020 May 14, 2020	BUY	$14.39 - $35.8 $889,704 - $2.21 Million	61,828 New	61,828 $1.61 Million

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.